AbSci (ABSI) AI Stock Analysis

• Market Cap: $449.61M
• Dividend Yield: N/A
• Average Volume (3M): 3.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: -33.09%
• EPS Growth: 3.38%
• Country: US
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 150,371,540
• 10 Day Avg. Volume: 2,862,820
• 30 Day Avg. Volume: 3,208,105
• PEG Ratio: 0.13
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 63.70
• P/FCF Ratio: -3.97
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 158.56
• Enterprise Value/Gross Profit: -8.75
• Enterprise Value/Ebitda: -4.30
• 1Y Price Target: $7.66
• Price Target Upside: 156.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $3.00 ▲(0.33% Upside)

Overall score is held back primarily by weak financial performance (unprofitability and ongoing cash burn). Technicals are also soft in the near term, and valuation metrics provide limited support due to losses and no dividend. The key offset is a more positive earnings-call outlook driven by ABS-201 pipeline momentum and partnering plans.

Positive Factors

Pipeline Expansion

The strategic focus on ABS-201's development in AGA and endometriosis represents a significant growth opportunity in multibillion-dollar markets, potentially enhancing long-term revenue streams.

Financial Position

A strong cash position provides financial stability and the ability to fund operations and strategic initiatives through 2028, supporting long-term growth and resilience.

AI-Driven Drug Discovery

Advancements in AI-driven drug discovery enhance competitive advantage by enabling innovative therapeutic solutions and attracting potential partnerships.

Negative Factors

Unprofitability

Ongoing unprofitability and negative cash flows pose risks to financial stability, potentially limiting investment in growth and innovation.

Revenue Decline

Declining revenue growth indicates challenges in market penetration and product adoption, impacting long-term business sustainability and profitability.

High R&D Expenses

High R&D expenses, while necessary for innovation, strain financial resources and may delay profitability, affecting long-term financial health.

AbSci Business Overview & Revenue Model

Company Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

How the Company Makes Money

AbSci generates revenue primarily through its contract development and manufacturing services, where it collaborates with pharmaceutical and biotech companies to produce proteins for research and therapeutic purposes. This includes providing services for protein engineering, optimization, and large-scale production. Additionally, AbSci earns revenue from partnerships and collaborations with major pharmaceutical companies, where it may receive milestone payments and royalties based on the success of developed products. The company's proprietary pipeline of therapeutic proteins also has the potential to contribute to revenue through licensing agreements or direct sales once products are commercialized.

AbSci Financial Statement Overview

Summary

Weak financial fundamentals: the income statement shows persistent unprofitability (negative gross/net margins and negative EBIT/EBITDA) and sharply declining revenue growth. Cash flow remains negative (operating and free cash flow burn), though leverage is limited, providing some balance-sheet flexibility despite negative ROE.

Income Statement

AbSci's income statement reflects significant challenges, with negative gross and net profit margins indicating unprofitability. The TTM data shows a sharp decline in revenue growth, exacerbating the financial strain. The company is struggling to convert revenue into profit, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio, suggesting limited leverage, which is a positive aspect. However, the negative return on equity indicates that the company is not generating returns for shareholders, and the equity ratio suggests a high reliance on equity financing.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash burn. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio is negative, highlighting inefficiencies in cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.81M	4.53M	5.72M	5.75M	4.78M	4.78M
Gross Profit	-50.98M	-57.92M	-41.85M	-53.16M	-39.80M	-6.67M
EBITDA	-103.91M	-94.10M	-79.68M	-93.71M	-67.68M	-12.59M
Net Income	-114.60M	-103.11M	-110.57M	-104.90M	-100.96M	-14.35M
Balance Sheet
Total Assets	244.99M	213.61M	217.30M	321.01M	426.19M	88.57M
Cash, Cash Equivalents and Short-Term Investments	152.47M	112.42M	97.66M	164.43M	252.57M	69.87M
Total Debt	6.22M	10.11M	15.88M	22.98M	20.01M	14.50M
Total Liabilities	34.65M	34.48M	41.12M	46.59M	60.09M	21.56M
Stockholders Equity	210.34M	179.13M	176.18M	274.41M	366.11M	67.00M
Cash Flow
Free Cash Flow	-81.94M	-72.81M	-65.50M	-97.51M	-98.64M	-13.15M
Operating Cash Flow	-80.71M	-72.40M	-64.64M	-81.34M	-60.60M	-10.97M
Investing Cash Flow	-50.66M	-41.58M	81.94M	-126.98M	-67.38M	-2.17M
Financing Cash Flow	103.09M	82.53M	-4.48M	5.24M	336.19M	70.97M

AbSci Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Negative. The current price of 2.99 is below the 20-day moving average (MA) of 3.25, below the 50-day MA of 3.31, and below the 200-day MA of 3.12, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 42.64 is Neutral, neither overbought nor oversold. The STOCH value of 37.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABSI.

AbSci Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAPT	60 Neutral	$1.60B	-5.21	-85.37%	―	―	50.23%
DSGN	55 Neutral	$581.60M	-8.60	-29.83%	―	―	-40.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	51 Neutral	$364.61M	-1.62	-60.52%	―	407.86%	30.35%
ADCT	48 Neutral	$447.20M	-2.49	―	―	6.35%	39.57%
FDMT	47 Neutral	$451.93M	-2.25	-45.38%	―	―	―
ABSI	46 Neutral	$449.61M	-3.31	-55.68%	―	-33.09%	3.38%

AbSci Corporate Events

Absci Showcases Generative AI Drug Platform and Pipeline

On January 14, 2026, Absci Corporation presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its generative AI-driven drug creation platform and the progress of its clinical pipeline. Management emphasized that Absci has already advanced three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease, positioning the company as a cost- and time-efficient alternative to traditional large pharma discovery models. The presentation underscored ABS-201 as a potential category-defining hair regrowth therapy based on prolactin receptor inhibition, supported by primate and human ex vivo data showing prolonged anagen phase, increased hair density and thickness, and potential restoration of pigmentation, and detailed a Phase 1/2a Australian trial designed to assess safety, tolerability, pharmacokinetics/pharmacodynamics, and early efficacy in up to 227 male and female participants with androgenetic alopecia. By showcasing its ability to de novo design antibodies against previously untargeted epitopes and by focusing on large commercially attractive indications with clear unmet need, Absci is seeking to strengthen its positioning as a next-generation discovery partner and developer, with potential implications for partners and investors looking for more capital-efficient routes to novel biologics.

The most recent analyst rating on (ABSI) stock is a Hold with a $4.32 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.

Absci Reports Q3 Results, Focuses on ABS-201

On November 12, 2025, Absci Corporation reported its third-quarter financial and operating results, highlighting significant advancements in its pipeline. The company is focusing on ABS-201, targeting androgenetic alopecia and endometriosis, with clinical trials scheduled for late 2025 and 2026. Absci’s strategic shift involves reallocating resources to ABS-201 due to its high unmet medical need and market potential, while exploring partnerships for ABS-101. The company reported a net loss of $28.7 million for the quarter but has sufficient cash reserves to fund operations until the first half of 2028.

The most recent analyst rating on (ABSI) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.

Absci Finalizes Milestone Distribution Agreement with SBGH

On October 31, 2025, Absci Corporation executed a Letter Agreement with SBGH, LLC, amending a previous Merger Agreement from June 4, 2021, involving Totient, Inc. This agreement finalizes the distribution of Milestone Consideration, with former Totient stockholders receiving approximately $7.6 million and Absci receiving about $8.7 million, impacting the financial settlements under the original merger terms.

The most recent analyst rating on (ABSI) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.